<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynne L Levitsky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Madhusmita Misra, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Type 1 diabetes mellitus (T1DM), one of the most common chronic diseases in childhood, is caused by insulin deficiency following destruction of the insulin-producing pancreatic beta cells. It most commonly presents in childhood, but one-fourth of cases are diagnosed in adults. T1DM remains the most common form of diabetes in childhood, despite the increasing rate of type 2 diabetes mellitus (T2DM) [<a href="#rid1">1,2</a>].</p><p>The epidemiology, presentation, and diagnosis of T1DM in children and adolescents are presented here. The pathogenesis of T1DM and the management and complications of childhood T1DM are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5817.html" rel="external">"Overview of the management of type 1 diabetes mellitus in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/97229.html" rel="external">"Hypoglycemia in children and adolescents with type 1 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5808.html" rel="external">"Diabetic ketoacidosis in children: Treatment and complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus"</a>.)</p><p></p><p>The assessment and management of individuals presenting during infancy with hyperglycemia also are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of childhood T1DM varies based upon geography, age, sex, family history, and ethnicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Geographical variation</strong> – The incidence of childhood T1DM varies worldwide [<a href="#rid3">3</a>]. The highest reported incidences of T1DM occur in Finland and Sardinia (45 to 65 per 100,000 children younger than the age of 15 years) [<a href="#rid3">3-5</a>]. In the United States, the annual incidence of T1DM in children and adolescents is 22.3 per 100,000 overall, with substantial differences between race/ethnic groups (27.3 per 100,000 in non-Hispanic White youth, 20.8 per 100,000 in Black youth, and 16.3 per 100,000 in Hispanic youth) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age and sex</strong> – The age of presentation of childhood-onset T1DM has a bimodal distribution, with one peak at four to six years of age and a second in early puberty (10 to 14 years of age)  (<a class="graphic graphic_figure graphicRef88297" href="/z/d/graphic/88297.html" rel="external">figure 1</a>) [<a href="#rid7">7-9</a>]. Overall, approximately 45 percent of children present before 10 years of age [<a href="#rid10">10</a>]. T1DM accounts for almost all cases of diabetes before 10 years of age, 90 percent of cases in children 10 to 14 years, and 80 percent in youth 15 to 19 years [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1">Although most autoimmune diseases are more common in females, there appears to be no sex difference in the overall incidence of childhood T1DM [<a href="#rid1">1,2</a>]. However, in some studies, T1DM occurs more frequently in males. Globally, the ratio of males to females diagnosed with T1DM in young adulthood is approximately 1.5:1 [<a href="#rid11">11</a>]. The same male to female ratio also was reported in children younger than six years of age in an observational study from Massachusetts [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time trends</strong> – Several reports suggest that the incidence of childhood T1DM is rising worldwide, with increases of 2 to 5 percent per year in Europe, the Middle East, and Australia [<a href="#rid4">4,13-16</a>]. In the United States, the incidence has been rising at approximately 2 percent per year (from 19.5 per 100,000 in 2002-2003 to 22.3 in 2014-2015)  (<a class="graphic graphic_figure graphicRef132714" href="/z/d/graphic/132714.html" rel="external">figure 2</a>) [<a href="#rid6">6</a>]. The prevalence rose from 1.48 per 1000 to 2.15 per 1000 over a similar time period [<a href="#rid2">2</a>]. The reasons for this trend remain unknown.</p><p></p><p class="bulletIndent1">The time trends within age groups vary among populations. A report using data from 17 European countries between 1989 and 2003 revealed a greater annual increase among younger children compared with adolescents [<a href="#rid15">15</a>]. By contrast, in the United States between 2001 and 2017, the annual change in prevalence slightly decreased for young children, while increasing for older children [<a href="#rid2">2</a>]. Similar decreases in trends among younger children born after 2000 were seen in studies from Sweden [<a href="#rid17">17</a>] and New Zealand [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H4821065"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Both genetic and environmental factors contribute to the risk of developing T1DM. (See  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Genetic susceptibility</span><span class="headingEndMark"> — </span>The lifetime risk of developing T1DM is significantly increased in close relatives of a patient with T1DM [<a href="#rid3">3,19-21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No family history – 0.4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Offspring of an affected mother – 1 to 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Offspring of an affected father – 3 to 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Offspring with both parents affected – Reported as high as 30 percent [<a href="#rid22">22,23</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Non-twin sibling of affected patient – 3 to 6 percent by age 20 years [<a href="#rid20">20</a>] and 10 percent by 60 years [<a href="#rid24">24</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Dizygotic twin – 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Monozygotic twin – 30 percent within 10 years of diagnosis of the first twin [<a href="#rid25">25</a>] and 65 percent concordance by age 60 years [<a href="#rid26">26</a>]</p><p></p><p>In the United States, there also are ethnic differences in incidence of T1DM [<a href="#rid2">2</a>]. In a study that sampled several large multiethnic populations in 2017, the highest prevalence (per 1000 children &lt;19 years) was seen in non-Hispanic White youth (2.79), followed by Black (2.18), Hispanic (1.56), Asian or Pacific Islander (0.76), and Native American youth (0.56)  (<a class="graphic graphic_figure graphicRef95197" href="/z/d/graphic/95197.html" rel="external">figure 3</a>) [<a href="#rid2">2</a>].</p><p>These observations of familial and ethnic risk factors are most likely the consequences of gene polymorphisms in the major histocompatibility complex or other genetic susceptibility regions. Details regarding genetic susceptibility and the genes that increase the risk of T1DM are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus", section on 'Genetic susceptibility'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Other possible risk factors</span><span class="headingEndMark"> — </span>In genetically susceptible individuals, exposure to one or more environmental agents (eg, viruses or foods) appears to trigger an immune response that ultimately causes destruction of the insulin-producing pancreatic beta cells. Identification of these factors should lead to a better understanding of the pathogenesis of the disease and aid in developing strategies to prevent T1DM [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1811.html" rel="external">"Type 1 diabetes mellitus: Prevention and disease-modifying therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p>A more complete description of environmental factors and their potential link to T1DM is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus", section on 'Environmental factors'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>For clinical purposes, T1DM has three initial presentations [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Classic new onset of polydipsia, polyuria, and weight loss with hyperglycemia and ketonemia (or ketonuria)</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic ketoacidosis (DKA)</p><p class="bulletIndent1"><span class="glyph">●</span>Silent (asymptomatic) incidental discovery</p><p></p><p>T1DM is now recognized to have four stages [<a href="#rid28">28,29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 1 – Beta cell autoimmunity (≥2 islet autoantibodies), normal blood glucose; no symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 2 – Beta cell autoimmunity (≥2 islet autoantibodies) and abnormal glucose tolerance; usually with no symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 3 – Beta cell autoimmunity and raised blood glucose above diagnostic thresholds; usually with symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 4 – Established/longstanding T1DM</p><p></p><p>Progression between the stages of T1DM is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1791.html" rel="external">"Type 1 diabetes mellitus: Disease prediction and screening"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Classic new onset</span><span class="headingEndMark"> — </span>Hyperglycemia without acidosis is the most common presentation of childhood T1DM in most populations. Patients typically present with the following symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria – Polyuria occurs when the serum glucose concentration rises significantly above 180 mg/dL (10 mmol/L), exceeding the renal threshold for glucose, which leads to increased urinary glucose excretion. Glycosuria causes osmotic diuresis (ie, polyuria) and hypovolemia. Polyuria may present as nocturia, bedwetting, or daytime incontinence in a previously continent child. In children who are not toilet trained, caregivers may note an increased frequency of wet diapers and/or diapers that are unusually heavy (wet).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polydipsia – Polydipsia is due to enhanced thirst because of increased serum osmolality from hyperglycemia and hypovolemia. Despite the hypovolemia, patients may not have the classic signs of dry mucus membranes or decreased skin turgor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss – Weight loss is a result of hypovolemia and increased catabolism. Insulin deficiency in diabetic children impairs glucose utilization in skeletal muscle and increases fat and muscle breakdown. Initially, appetite is increased, but over time, children are more thirsty than hungry and ketosis leads to nausea and anorexia, contributing to weight loss.</p><p></p><p>Patients with these symptoms usually present in the ambulatory setting appearing slightly ill, with vague complaints such as weight loss and lethargy [<a href="#rid12">12</a>]. In a study from Ireland, the mean duration of symptoms before presentation was 10 days [<a href="#rid30">30</a>]. The classic symptoms of polyuria and polydipsia are present in more than 90 percent of patients, but these are not always the initial complaints and may become apparent only after asking specifically about nocturia and bedwetting, increased frequency and/or unusually wet diapers, and persistent thirst. Weight loss is a presenting symptom in approximately one-half of children.</p><p>Other presentations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Perineal candidiasis – This is a relatively common presenting symptom in young children and in girls [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute visual disturbances – These are common because of alterations in the osmotic milieu of the lens and, to a lesser extent, the aqueous and vitreous humors, leading to changes in refractive index [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cataracts – Cataracts occasionally develop in children with longstanding hyperglycemia and may be a presenting feature [<a href="#rid32">32-34</a>]. In a large multicenter study in individuals 0.5 to 21 years old, cataracts were noted in 0.25 percent of children and adolescents with T1DM; they were more common in females and patients with higher hemoglobin A1c (A1C) and older age at diabetes onset [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/6270.html" rel="external">"Cataract in children"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Diabetic ketoacidosis</span><span class="headingEndMark"> — </span>DKA (hyperglycemia and ketoacidosis) is the second most common form of presentation for T1DM in most populations. Symptoms are similar but usually more severe than those of patients without acidosis. In addition to polyuria, polydipsia, and weight loss, patients with ketoacidosis may present with a fruity-smelling breath and neurologic findings, including drowsiness and lethargy. DKA can be misinterpreted as an acute vomiting illness because classic pediatric symptoms of dehydration (decreased urination) are masked by the polyuria that is associated with glycosuria. (See  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis", section on 'Signs and symptoms'</a>.)</p><p>The reported frequency of DKA as the initial presentation for childhood T1DM is approximately 30 percent but varies from 15 to 70 percent [<a href="#rid35">35-37</a>]. Young children (&lt;6 years of age) or those from an adverse socioeconomic background are more likely to have DKA as their initial presentation of T1DM. Among children younger than age three years, more than one-half had DKA as their initial presentation of T1DM [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis", section on 'Epidemiology'</a>.)</p><p>Children with DKA require hospitalization, rehydration, and insulin replacement therapy. (See  <a class="medical medical_review" href="/z/d/html/5808.html" rel="external">"Diabetic ketoacidosis in children: Treatment and complications"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Silent presentation</span><span class="headingEndMark"> — </span>Some children will be diagnosed with T1DM before the onset of clinical symptoms. This presentation is least common and typically occurs in children who have another close family member with T1DM and are being closely monitored. The diagnosis often is made by either a family member or clinician with a high index of suspicion. Children with affected close relatives also may undergo pancreatic autoantibody screening to assess risk for the disease [<a href="#rid39">39</a>], although this is not a clinical care recommendation (see  <a class="medical medical_review" href="/z/d/html/1791.html" rel="external">"Type 1 diabetes mellitus: Disease prediction and screening"</a>). These children may be classified as having stage 1 or stage 2 diabetes, using International Society for Pediatric and Adolescent Diabetes guidelines [<a href="#rid29">29</a>]. The diagnosis of stage 2 diabetes is made based upon an elevated blood glucose concentration using the criteria outlined below. (See <a class="local">'Approach to diagnosis'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H13"><span class="h3">Infants</span><span class="headingEndMark"> — </span>A variety of disorders can cause hyperglycemia during infancy. Although autoimmune classic T1DM can occur in the first year of life, neonatal diabetes is uncommonly, if ever, autoimmune in nature. Neonatal diabetes is a rare disorder caused by one of several genetic defects in pancreatic development or beta cell function. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Neonatal diabetes mellitus'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Young children</span><span class="headingEndMark"> — </span>Young children (eg, &lt;6 years of age) are more vulnerable to dehydration compared with older children because they are less able to compensate for pathologic processes by seeking fluids and increasing fluid intake (to replace ongoing urinary losses) [<a href="#rid12">12</a>]. In addition, young children are more likely to present with DKA because health care personnel and families less often suspect diabetes in this age group. This leads to a prolonged duration of illness and more severe metabolic decompensation before diagnosis [<a href="#rid12">12,30,38,40,41</a>].</p><p>Children in this age group also have polydipsia and polyuria, but these symptoms are difficult to detect if the child is still in diapers or is nonverbal and unable to communicate thirst. Therefore, it is often difficult to recognize these symptoms of hyperglycemia in young children, especially those younger than two years of age [<a href="#rid12">12</a>]. The history or presence of prolonged or recurrent candidal infection (usually in the diaper area) is an important clue that should raise suspicion about the possibility of diabetes mellitus in young children. Candidal infection was present at diagnosis in a significant proportion of children younger than six years with T1DM and especially in those younger than two years of age [<a href="#rid12">12</a>].</p><p>These patients often have been seen by a clinician for nonspecific complaints before the diagnosis [<a href="#rid12">12</a>]. In this vulnerable age group, a high index of suspicion is required for early diagnosis. When a young child presents for evaluation of dehydration, abdominal pain, or fatigue, the clinician should include diabetes in the differential diagnosis and consider measuring serum glucose and testing for glucosuria.</p><p class="headingAnchor" id="H15"><span class="h1">APPROACH TO DIAGNOSIS</span><span class="headingEndMark"> — </span>T1DM is one of several different types of diabetes mellitus. The initial step is to diagnose diabetes. The second step is to differentiate T1DM from other causes of diabetes, based upon the clinical presentation of the patient and laboratory studies. (See <a class="local">'Distinguishing type 1 from type 2 diabetes'</a> below and <a class="local">'Other causes of diabetes'</a> below.)</p><p class="headingAnchor" id="H4821743"><span class="h2">Diagnostic criteria for diabetes</span><span class="headingEndMark"> — </span>Diabetes mellitus is diagnosed based upon one of the following four signs of abnormal glucose metabolism  (<a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">table 1</a>) [<a href="#rid3">3,42,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting plasma glucose ≥126 mg/dL (7 mmol/L) on more than one occasion. Fasting is defined as no caloric intake for at least eight hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Random venous plasma glucose ≥200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma glucose ≥200 mg/dL (11.1 mmol/L) measured two hours after a glucose load of 1.75 g/kg (maximum dose of 75 g) in an oral glucose tolerance test. Most children and adolescents are symptomatic and have plasma glucose concentrations well above ≥200 mg/dL (11.1 mmol/L); thus, an oral glucose tolerance test is seldom necessary to diagnose T1DM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glycated hemoglobin (A1C) ≥6.5 percent (using an assay that is certified by the National Glycohemoglobin Standardization Program). This criterion should be confirmed by another measure of hyperglycemia.</p><p></p><p>Unless unequivocal symptomatic hyperglycemia is present, the diagnosis should be confirmed by repeat testing.</p><p>In the absence of continuous glucose monitoring, A1C is a valuable method to monitor glycemic control. A1C measures the percent of hemoglobin A bound to glucose via non-enzymatic glycation and is a useful index of mean glycemic control for 10 to 12 weeks before the time of measurement. In one study from Germany, all children with symptomatic new-onset T1DM had an A1C ≥6.35 percent, whereas those with transient hyperglycemia had A1C values ranging from 4.5 to 6.1 percent [<a href="#rid44">44</a>]. Individuals with abnormal hemoglobins or rapid destruction of red blood cells may have a measured A1C value that does not accurately reflect their average blood sugar values. The accuracy of measurements in individuals with abnormal hemoglobins will improve with the use of improved techniques for assessing A1C and with standardization of A1C measurements. For example, hemoglobin variants and derivatives interfere very minimally with the commercially available boronate affinity chromatography technique [<a href="#rid45">45</a>]. However, rapid turnover of hemoglobin will still affect the reported A1C level. (See  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'A1C'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Distinguishing type 1 from type 2 diabetes</span><span class="headingEndMark"> — </span>Once a diagnosis of diabetes is made, the next step is to distinguish T1DM from type 2 diabetes mellitus (T2DM). T1DM is characterized primarily by insulin deficiency, whereas T2DM is characterized primarily by insulin resistance with relative insulin deficiency. As the prevalence of obesity and the incidence of T2DM increase in children and adolescents, it becomes increasingly important to consider both types. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes"</a>.)</p><p>No set of criteria or diagnostic test can consistently distinguish between T1DM and T2DM. Therefore, differentiating between the two types is based upon a combination of the clinical presentation and history, often supported by laboratory studies  (<a class="graphic graphic_table graphicRef59370" href="/z/d/graphic/59370.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3994428028"><span class="h3">Clinical characteristics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Body habitus – Patients with T2DM usually have obesity (body mass index ≥95<sup>th</sup> percentile for age and sex). In contrast, children with T1DM are less likely to have excess body weight and often have a recent history of weight loss, although up to 25 percent are overweight (body mass index ≥85<sup>th</sup> to 95<sup>th</sup> percentile) [<a href="#rid46">46</a>]. Patients with new-onset T2DM may also have a history of recent weight loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age – Patients with T2DM generally present after the onset of puberty, whereas those with T1DM often present at an earlier age. Approximately 45 percent of children with T1DM present before 10 years of age [<a href="#rid10">10</a>]. By contrast, almost all cases of T2DM present after 10 years of age  (<a class="graphic graphic_figure graphicRef88297" href="/z/d/graphic/88297.html" rel="external">figure 1</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance – Patients with T2DM frequently have acanthosis nigricans (a sign of insulin resistance), hypertension, dyslipidemia, and polycystic ovary syndrome (in girls). These findings are less likely in children with T1DM. As an example, in studies in the United States, 50 to 90 percent of youth diagnosed with T2DM have acanthosis nigricans [<a href="#rid47">47,48</a>]. Among those clinically diagnosed with T1DM, up to 25 percent have biochemical evidence of insulin resistance and approximately 12 percent have acanthosis nigricans [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history – Up to 10 percent of patients with T1DM have an affected close relative, whereas 75 to 90 percent of those with T2DM have an affected close relative [<a href="#rid47">47,49</a>].</p><p></p><p class="headingAnchor" id="H1410351788"><span class="h3">Laboratory testing</span><span class="headingEndMark"> — </span>We suggest including the following laboratory tests in the evaluation, to help distinguish between type 1 and type 2 diabetes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatic autoantibodies</strong> – Measure autoantibodies against GAD65 (glutamic acid decarboxylase 65), IA2 (the 40K fragment of tyrosine phosphatase), insulin, and ZnT8 (zinc transporter 8) [<a href="#rid3">3</a>]. This panel of tests should be performed at the time of presentation, before or soon after starting insulin therapy. Insulin antibodies may develop approximately 10 to 14 days after exposure to exogenous insulin.</p><p></p><p class="bulletIndent1">Most patients with T1DM have one or more of the above pancreatic autoantibodies, indicating autoimmune destruction of pancreatic beta cells; this is sometimes referred to as type 1A diabetes  (<a class="graphic graphic_figure graphicRef129475" href="/z/d/graphic/129475.html" rel="external">figure 4</a>) [<a href="#rid48">48</a>]. A minority of patients with clinical features of T1DM have no detectable autoantibodies and are categorized as having type 1B diabetes. In these patients, there is no evidence of autoimmune beta cell destruction and no other cause has been identified. Conversely, up to 30 percent of individuals with clinical characteristics of T2DM have positive autoantibodies and may have a slowly progressive type of autoimmune diabetes [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin and C-peptide levels</strong> – We measure these levels for children with clinical characteristics that raise the possibility of T2DM. In a newly diagnosed patient, these tests should be performed after the child has recovered from the initial hyperglycemic stress because insulin and C-peptide levels may be suppressed by severe hyperglycemia (glucose toxicity) and acute illness.</p><p></p><p class="bulletIndent1">In children with T1DM, levels of fasting insulin and C-peptide are inappropriately low relative to the concomitant plasma glucose concentration (ie, low or in the normal range despite hyperglycemia). By contrast, high fasting insulin and C-peptide levels suggest T2DM.</p><p></p><p>Some patients may have mixed features and are difficult to classify, highlighting the heterogeneity of diabetes. As an example, in a registry study in the United States, pediatric diabetes was classified based upon the presence or absence of beta cell autoimmunity and the presence or absence of insulin sensitivity [<a href="#rid48">48</a>]. More than 70 percent of patients fell into traditional categories of autoimmune and insulin-sensitive T1DM (55 percent) or nonautoimmune and insulin-resistant T2DM (16 percent). An additional 20 percent had both autoimmunity and insulin resistance, a pattern typical for patients with obesity and T1DM. The remaining 10 percent of patients were insulin sensitive in the absence of islet cell autoimmunity, most of whom were clinically categorized as T1DM (ie, type 1B diabetes) and the remainder as T2DM (suggesting that these patients need additional evaluation for the possibility of monogenic diabetes, formerly referred to as maturity-onset diabetes of the young [MODY]). (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Distinguishing type 1 from type 2 diabetes'</a> and <a class="local">'Other causes of diabetes'</a> below.)</p><p class="headingAnchor" id="H4821788"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H4821796"><span class="h2">Other causes of hyperglycemia</span><span class="headingEndMark"> — </span>In the previously healthy child, diabetes mellitus is by far the most common cause of clinically significant hyperglycemia. Other considerations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Critically ill patients – Patients with septic shock or other critical illnesses often have abnormalities in glycemic control, leading to either hypoglycemia or hyperglycemia. (See  <a class="medical medical_review" href="/z/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Manage glucose abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medication – Children receiving intravenous infusions containing glucose, or those who receive acute sympathomimetic agents or high-dose glucocorticoids, may display elevations in blood glucose that revert to normal after treatment is complete.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal hyperglycemia – Causes of hyperglycemia in a neonate include excessive glucose infusion, prematurity, stress, sepsis, drugs, and transient or permanent neonatal diabetes mellitus. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia"</a>.)</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Other causes of diabetes</span><span class="headingEndMark"> — </span>T1DM is distinguished from other diseases that cause diabetes by patient characteristics, history, and laboratory studies. This approach is similar to that used to differentiate type 1 from type 2 diabetes, as discussed above. (See <a class="local">'Distinguishing type 1 from type 2 diabetes'</a> above.)</p><p>The following diseases that cause diabetes are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monogenic diabetes</strong> – Monogenic diabetes (formerly referred to as maturity-onset diabetes of the young [MODY]) is a clinically heterogeneous disorder characterized by noninsulin-dependent diabetes presenting at a young age, with autosomal dominant transmission and lack of autoantibodies. Many different genetic abnormalities have been identified, each leading to a different type of disease. Monogenic diabetes should be suspected in a patient presenting with noninsulin-dependent diabetes at a young age (&lt;25 years), with autosomal dominant transmission across three generations, lack of islet autoantibodies, and lack of acanthosis nigricans. The diagnosis of monogenic diabetes is made by performing diagnostic genetic testing through direct sequencing of the gene. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Monogenic diabetes (formerly called maturity onset diabetes of the young)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diseases affecting the exocrine pancreas</strong> – Cystic fibrosis, hereditary hemochromatosis, and chronic pancreatitis. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Diseases of the exocrine pancreas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine abnormalities in glucose regulation</strong> – Cushing syndrome, growth hormone excess, glucagon-secreting tumors, catecholamine excess in pheochromocytoma. With the exception of Cushing syndrome, these are all extremely rare. This possibility should be evaluated in patients presenting with Cushingoid features (such as central obesity, facial plethora, dorsocervical fat pad, and delayed linear growth). This is usually best accomplished by measuring 24-hour urinary cortisol excretion or salivary cortisol at 11:00 PM or midnight two or more times or an overnight low-dose <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> suppression test; additional testing may be required. Two of these three tests need to be positive for a diagnosis of Cushing syndrome. It is important to recognize that children with Cushing syndrome may not manifest the classic features seen in adults. However, a deceleration of growth velocity despite increasing weight should raise concern for Cushing syndrome in a growing child. It is very rare for a child with Cushing syndrome to present with hyperglycemia, although it is relatively common in adults. (See  <a class="medical medical_review" href="/z/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Glucose intolerance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced diabetes</strong> – A number of drugs (eg, glucocorticoids, human immunodeficiency virus [HIV] protease inhibitors, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>, L-asparaginase, and <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">tacrolimus</a>) and atypical antipsychotic agents can impair glucose tolerance by inhibiting insulin secretion, increasing hepatic glucose production, or causing insulin resistance  (<a class="graphic graphic_table graphicRef67257" href="/z/d/graphic/67257.html" rel="external">table 3</a>). In addition, newer immune checkpoint inhibitors used in the treatment of melanoma and other malignancies have been associated with the development of insulin-deficient diabetes [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Drug-induced hyperglycemia'</a> and  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus", section on 'Treatment with checkpoint inhibitor immunotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal diabetes mellitus</strong> – Neonatal diabetes is a rare cause of hyperglycemia in infants. It can be transient or permanent and usually is caused by mutations in one of several genes that encode proteins that affect the function of the pancreatic beta cell (eg, proteins that are subunits of the ATP-sensitive potassium channel). Most of the infants are small for gestational age, and they present with weight loss, volume depletion, hyperglycemia, and glucosuria with or without ketonuria and ketoacidosis. The natural history and management of diabetes in these infants depends on the genetic defect, as discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Neonatal diabetes mellitus'</a>.)</p><p></p><p class="headingAnchor" id="H2263024192"><span class="h2">Glycosuria without hyperglycemia</span><span class="headingEndMark"> — </span>Patients with renal glucosuria or Fanconi syndrome will present with glycosuria but have normal plasma glucose concentrations. </p><p class="headingAnchor" id="H3964208951"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a>.)</p><p class="headingAnchor" id="H439284"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15401.html" rel="external">"Patient education: Type 1 diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16597.html" rel="external">"Patient education: My child has diabetes: How will we manage? (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16600.html" rel="external">"Patient education: Giving your child insulin (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1736.html" rel="external">"Patient education: Type 1 diabetes: Overview (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Type 1 diabetes mellitus (T1DM) is one of the most common chronic diseases of childhood. In the United States, T1DM accounts for almost all cases of diabetes among children &lt;10 years and approximately 80 percent of cases in children 10 to 19 years  (<a class="graphic graphic_figure graphicRef88297" href="/z/d/graphic/88297.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The incidence of childhood T1DM varies worldwide, ranging from 0.1 to 65 per 100,000 children younger than the age of 15 years. The age of presentation has a bimodal distribution, with peaks at four to six years of age and between 10 and 14 years of age. In the United States, the incidence of T1DM is 22.3 per 100,000 annually, with the highest rates in non-Hispanic White children and adolescents  (<a class="graphic graphic_figure graphicRef95197" href="/z/d/graphic/95197.html" rel="external">figure 3</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although there appears to be no overall sex difference in the incidence of childhood T1DM, in select populations (eg, European adolescents), there seems to be an increased risk for males (3:2 male-to-female ratio). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of T1DM is moderately increased in children with an affected close relative, which is most likely due to gene polymorphisms in the major histocompatibility complex and other susceptibility areas. (See <a class="local">'Genetic susceptibility'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although exposure to an environmental agent(s) in genetically susceptible individuals appears to trigger the destruction of the insulin-producing pancreatic beta cell, no factor(s) has been definitively identified. (See <a class="local">'Risk factors'</a> above and  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Childhood T1DM usually presents with the classic signs and symptoms resulting from hyperglycemia, including polyuria, polydipsia, weight loss, and lethargy. Diabetic ketoacidosis (DKA) is often the initial presentation for T1DM, especially in children younger than six years of age and in children of all ages with poor access to health care. Children also may be identified by screening for the disease before the onset of symptoms. (See <a class="local">'Clinical presentation'</a> above and  <a class="medical medical_review" href="/z/d/html/1791.html" rel="external">"Type 1 diabetes mellitus: Disease prediction and screening"</a>.)</p><p></p><p class="bulletIndent1">In young children, the diagnosis of T1DM is often missed because it may be difficult to recognize the symptoms of hyperglycemia in this age group. Children younger than two years of age are particularly likely to have a delay in diagnosis. In these patients, a history or presence of prolonged candidal infection should prompt consideration of diabetes mellitus and measurement of blood and urine glucose concentrations. (See <a class="local">'Young children'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of diabetes is based upon any one of four detected abnormalities of glucose metabolism  (<a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">table 1</a>) (see <a class="local">'Diagnostic criteria for diabetes'</a> above and  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fasting plasma glucose ≥126 mg/dL (7 mmol/L) on at least two occasions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms of hyperglycemia and a plasma glucose ≥200 mg/dL (11.1 mmol/L)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plasma glucose ≥200 mg/dL (11.1 mmol/L) measured two hours after a standard glucose load in an oral glucose tolerance test</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glycated hemoglobin (A1C) ≥6.5 percent – This criterion should be confirmed in children by another measure of hyperglycemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – T1DM often can be distinguished from other causes of diabetes (such as T2DM) by clinical presentation and laboratory studies  (<a class="graphic graphic_table graphicRef59370" href="/z/d/graphic/59370.html" rel="external">table 2</a>). Although no one diagnostic test can distinguish between the two types of diabetes, T1DM is suggested by the presence of serum autoantibodies against islet cells and by inappropriately low fasting C-peptide and insulin levels with concomitant hyperglycemia. (See <a class="local">'Distinguishing type 1 from type 2 diabetes'</a> above and <a class="local">'Other causes of diabetes'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. N Engl J Med 2017; 376:1419.</a></li><li><a class="nounderline abstract_t">Lawrence JM, Divers J, Isom S, et al. Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. JAMA 2021; 326:717.</a></li><li><a class="nounderline abstract_t">Libman I, Haynes A, Lyons S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 2022; 23:1160.</a></li><li><a class="nounderline abstract_t">Harjutsalo V, Sund R, Knip M, Groop PH. Incidence of type 1 diabetes in Finland. JAMA 2013; 310:427.</a></li><li><a class="nounderline abstract_t">Songini M, Mannu C, Targhetta C, Bruno G. Type 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data. Acta Diabetol 2017; 54:9.</a></li><li><a class="nounderline abstract_t">Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in Incidence of Type 1 and Type 2 Diabetes Among Youths - Selected Counties and Indian Reservations, United States, 2002-2015. MMWR Morb Mortal Wkly Rep 2020; 69:161.</a></li><li><a class="nounderline abstract_t">Felner EI, Klitz W, Ham M, et al. Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. Pediatr Diabetes 2005; 6:213.</a></li><li><a class="nounderline abstract_t">Durruty P, Ruiz F, García de los Ríos M. Age at diagnosis and seasonal variation in the onset of insulin-dependent diabetes in Chile (Southern hemisphere). Diabetologia 1979; 17:357.</a></li><li><a class="nounderline abstract_t">Elamin A, Omer MI, Zein K, Tuvemo T. Epidemiology of childhood type I diabetes in Sudan, 1987-1990. Diabetes Care 1992; 15:1556.</a></li><li><a class="nounderline abstract_t">Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.</a></li><li><a class="nounderline abstract_t">Diaz-Valencia PA, Bougnères P, Valleron AJ. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health 2015; 15:255.</a></li><li><a class="nounderline abstract_t">Quinn M, Fleischman A, Rosner B, et al. Characteristics at diagnosis of type 1 diabetes in children younger than 6 years. J Pediatr 2006; 148:366.</a></li><li><a class="nounderline abstract_t">Mamoulakis D, Galanakis E, Bicouvarakis S, et al. Epidemiology of childhood type I diabetes in Crete, 1990-2001. Acta Paediatr 2003; 92:737.</a></li><li><a class="nounderline abstract_t">Karvonen M, Pitkäniemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 1999; 22:1066.</a></li><li><a class="nounderline abstract_t">Patterson CC, Dahlquist GG, Gyürüs E, et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027.</a></li><li><a class="nounderline abstract_t">Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013; 13:795.</a></li><li><a class="nounderline abstract_t">Berhan Y, Waernbaum I, Lind T, et al. Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden. Diabetes 2011; 60:577.</a></li><li><a class="nounderline abstract_t">Derraik JG, Reed PW, Jefferies C, et al. Increasing incidence and age at diagnosis among children with type 1 diabetes mellitus over a 20-year period in Auckland (New Zealand). PLoS One 2012; 7:e32640.</a></li><li><a class="nounderline abstract_t">Tillil H, Köbberling J. Age-corrected empirical genetic risk estimates for first-degree relatives of IDDM patients. Diabetes 1987; 36:93.</a></li><li><a class="nounderline abstract_t">Steck AK, Barriga KJ, Emery LM, et al. Secondary attack rate of type 1 diabetes in Colorado families. Diabetes Care 2005; 28:296.</a></li><li><a class="nounderline abstract_t">Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.</a></li><li><a class="nounderline abstract_t">Guo SW, Tuomilehto J. Preferential transmission of type 1 diabetes from parents to offspring: fact or artifact? Genet Epidemiol 2002; 23:323.</a></li><li><a class="nounderline abstract_t">Tuomilehto J, Podar T, Tuomilehto-Wolf E, Virtala E. Evidence for importance of gender and birth cohort for risk of IDDM in offspring of IDDM parents. Diabetologia 1995; 38:975.</a></li><li><a class="nounderline abstract_t">Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004; 364:1699.</a></li><li><a class="nounderline abstract_t">Olmos P, A'Hern R, Heaton DA, et al. The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. Diabetologia 1988; 31:747.</a></li><li><a class="nounderline abstract_t">Redondo MJ, Jeffrey J, Fain PR, et al. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 2008; 359:2849.</a></li><li><a class="nounderline abstract_t">Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005; 52:1553.</a></li><li><a class="nounderline abstract_t">Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38:1964.</a></li><li><a class="nounderline abstract_t">Besser REJ, Bell KJ, Couper JJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes 2022; 23:1175.</a></li><li><a class="nounderline abstract_t">Roche EF, Menon A, Gill D, Hoey H. Clinical presentation of type 1 diabetes. Pediatr Diabetes 2005; 6:75.</a></li><li><a class="nounderline abstract_t">Sonmez B, Bozkurt B, Atmaca A, et al. Effect of glycemic control on refractive changes in diabetic patients with hyperglycemia. Cornea 2005; 24:531.</a></li><li><a class="nounderline abstract_t">Falck A, Laatikainen L. Diabetic cataract in children. Acta Ophthalmol Scand 1998; 76:238.</a></li><li><a class="nounderline abstract_t">Datta V, Swift PG, Woodruff GH, Harris RF. Metabolic cataracts in newly diagnosed diabetes. Arch Dis Child 1997; 76:118.</a></li><li><a class="nounderline abstract_t">Reiter UM, Eckert AJ, Dunstheimer D, et al. Cataract in children and adolescents with type 1 diabetes. Insights from the German/Austrian DPV registry. Pediatr Diabetes 2022; 23:362.</a></li><li><a class="nounderline abstract_t">Dabelea D, Rewers A, Stafford JM, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics 2014; 133:e938.</a></li><li><a class="nounderline abstract_t">Glaser N, Fritsch M, Priyambada L, et al. ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes 2022; 23:835.</a></li><li><a class="nounderline abstract_t">Cherubini V, Grimsmann JM, Åkesson K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia 2020; 63:1530.</a></li><li><a class="nounderline abstract_t">Klingensmith GJ, Tamborlane WV, Wood J, et al. Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth. J Pediatr 2013; 162:330.</a></li><li><a class="nounderline abstract_t">Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004; 27:1399.</a></li><li><a class="nounderline abstract_t">Mallare JT, Cordice CC, Ryan BA, et al. Identifying risk factors for the development of diabetic ketoacidosis in new onset type 1 diabetes mellitus. Clin Pediatr (Phila) 2003; 42:591.</a></li><li><a class="nounderline abstract_t">Neu A, Willasch A, Ehehalt S, et al. Ketoacidosis at onset of type 1 diabetes mellitus in children--frequency and clinical presentation. Pediatr Diabetes 2003; 4:77.</a></li><li><a class="nounderline abstract_t">Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2017; 40:S11.</a></li><li><a class="nounderline abstract_t">Ehehalt S, Gauger N, Blumenstock G, et al. Hemoglobin A1c is a reliable criterion for diagnosing type 1 diabetes in childhood and adolescence. Pediatr Diabetes 2010; 11:446.</a></li><li><a class="nounderline abstract_t">Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47:153.</a></li><li><a class="nounderline abstract_t">Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11:4.</a></li><li><a class="nounderline abstract_t">Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136:664.</a></li><li><a class="nounderline abstract_t">Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.</a></li><li><a class="nounderline abstract_t">Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96:159.</a></li><li><a class="nounderline abstract_t">Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33:1970.</a></li><li><a class="nounderline abstract_t">Marchand L, Disse E, Dalle S, et al. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors. Acta Diabetol 2019; 56:1239.</a></li></ol></div><div id="topicVersionRevision">Topic 5816 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28402773" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34427600" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36537527" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23917294" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of type 1 diabetes in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639869" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Type 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32053581" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Trends in Incidence of Type 1 and Type 2 Diabetes Among Youths - Selected Counties and Indian Reservations, United States, 2002-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390390" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/395001" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Age at diagnosis and seasonal variation in the onset of insulin-dependent diabetes in Chile (Southern hemisphere).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1468286" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiology of childhood type I diabetes in Sudan, 1987-1990.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595272" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of diabetes in youth in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25849566" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Global epidemiology of type 1 diabetes in young adults and adults: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16615969" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Characteristics at diagnosis of type 1 diabetes in children younger than 6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12856988" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidemiology of childhood type I diabetes in Crete, 1990-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388969" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481249" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24072479" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The emerging global epidemic of type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270269" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22389717" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increasing incidence and age at diagnosis among children with type 1 diabetes mellitus over a 20-year period in Auckland (New Zealand).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3792666" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Age-corrected empirical genetic risk estimates for first-degree relatives of IDDM patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677782" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Secondary attack rate of type 1 diabetes in Colorado families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16644656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12432501" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Preferential transmission of type 1 diabetes from parents to offspring: fact or artifact?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7589885" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evidence for importance of gender and birth cohort for risk of IDDM in offspring of IDDM parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15530631" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3240835" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109586" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Concordance for islet autoimmunity among monozygotic twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301083" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Type 1 diabetes mellitus: etiology, presentation, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26404926" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36177823" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963033" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical presentation of type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15968156" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of glycemic control on refractive changes in diabetic patients with hyperglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591961" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diabetic cataract in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068299" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metabolic cataracts in newly diagnosed diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35064955" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cataract in children and adolescents with type 1 diabetes. Insights from the German/Austrian DPV registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24685959" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36250645" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32382815" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901739" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15161795" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14552517" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Identifying risk factors for the development of diabetic ketoacidosis in new onset type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655263" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ketoacidosis at onset of type 1 diabetes mellitus in children--frequency and clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15616254" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27979889" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : 2. Classification and Diagnosis of Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20149124" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hemoglobin A1c is a reliable criterion for diagnosing type 1 diabetes in childhood and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159762" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473302" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802501" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636800" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20962021" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519658" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31423559" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
